Printer Friendly


 SEATTLE, June 7 /PRNewswire/ -- Medical Investments Northwest (MINW), a conference for institutional investors, will be held Oct. 18-19, 1993, at the Stouffer Madison Hotel, Seattle. The invitation-only conference will feature comprehensive presentations by public and private medical companies based in the Pacific Northwest, including: ATL; Cell Therapeutics; CellPro; Epitope; ICOS; Immunex; InControl; MicroProbe; NeoRx; ProCyte; Quadra Logic Technologies; Targeted Genetics and Xillix Technologies.
 The one and one half day conference is structured to provide an in-depth review of participating companies' technological focus, product development progress, strategic direction, business development plans and financial position. Attendees also will have opportunities to meet with management teams throughout the meeting. Featured keynote speakers to be announced will address issues central to the health care industry.
 "We are proud of our strong and innovative biotechnology and medical technology industries in Washington State, and we fully support their continued growth," said Governor Mike Lowry of Washington State. "We have an excellent university system which provides not only top- notch employees, but excellent research and development for these dynamic companies."
 The growth of the conference underscores the increasingly significant role the Pacific Northwest is playing in the development and delivery of innovative biotechnology and medical device products. The medical technology corridor, ranging from southern British Columbia through Oregon with Washington State, and, particularly Greater Seattle, serving as a hub, has experienced rapid evolution spurred by a variety of factors, including a formidable university basic research infrastructure, a strong entrepreneurial culture, an attractive business and living environment and governmental support.
 Statistics on the growth and vitality of this sector within the Northwest Region provide a sharp contrast to many other industries. Washington State now has more than 60 biotechnology companies alone, employing approximately 5,000 personnel, a work force which grew at the rate of 26 percent or 12 times the statewide rate in the 1990-1992 period. These figures do not reflect medical device and other health care manufacturers or divisions of large conglomerates. The Seattle metro area has the sixth largest concentration of biomedical firms in the United States. The State of Oregon has 33 bioscience companies which, along with the state's research centers, are employing over 2,000 Oregonians, concentrated in the Willamette Valley and the Portland metro area. British Columbia has nearly 100 biotechnology companies and 30 of these firms specialize in the biomedical field.
 The first MINW conference was held in September of last year and the success of the event prompted the organizers to arrange an expanded program for 1993. Unlike most institutional investor seminars, the MINW meeting is developed and hosted by the participating companies.
 The following provides a brief description of participating companies:
 -- ATL (Advanced Technology Laboratories), with headquarters in Bothell, Wash., is a worldwide leader in the development, manufacture, marketing and service of medical ultrasound systems. The company, with revenues of $324 million in 1992, employs over 2,00 people at locations around the world. ATL stock is traded on the NASDAQ National Market System under the symbol ATLI.
 -- Cell Therapeutics, Inc., Seattle, is a biopharmaceutical company focused on development and commercialization of proprietary small molecule pharmaceuticals targeting oncologic and immune diseases.
 -- CellPro, Incorporated, of Bothell, Wash., (NASDAQ: CPRO) is a leading cell therapy company specializing in the development, manufacturing, and marketing of continuous-flow, cell-selection systems for use in a variety of therapeutic, diagnostic, and research applications.
 -- Epitope, Inc. (AMEX: EPT) is a Beaverton, Ore., corporation using biotechnology to develop diagnostic products for the detection of AIDS and other indications, and, through its agricultural unit, Agritope, Inc., superior new plant varieties.
 -- ICOS Corporation (NASDAQ: ICOS) is a Seattle-based biopharmaceutical company founded to develop medications for the treatment of chronic inflammatory diseases. Primary targets of the company's research and drug development programs include asthma, multiple sclerosis and rheumatoid arthritis.
 -- Immunex Corporation, Seattle, (NASDAQ: IMNX) is a biopharmaceutical company focused on the research, development, manufacture and marketing of products to treat cancer and autoimmune diseases.
 -- InControl, Incorporated, Redmond, Wash., is a cardiovascular device company developing unique implantable products for the diagnosis, prevention, and control of irregular or rapid heart rhythms.
 -- MicroProbe Corporation, Bothell, Wash., produces DNA-probe based systems for the rapid identification of infectious-disease microorganisms, and is involved in the discovery and development of new classes of therapeutics that selectively block genes and disease-causing proteins of chronic viral infections and certain cancers.
 -- NeoRx Corporation, Seattle, (NASDAQ: NERX) develops targeted biopharmaceutical products that detect and treat human illnesses with a focus on cancer and restenosis after coronary angioplasty. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac(R) Small Cell Lung Cancer Imaging Product and has completed a phase III trial for a non-small cell lung cancer imaging agent.
 -- ProCyte Corporation, Kirkland, Wash., (NASDAQ-NMS: PRCY), is a biopharmaceutical company engaged in the development of a new class of proprietary peptide-copper compounds for human therapeutic products, including wound healing, peptic ulcer prevention and inflammatory bowel disease applications. The company has two drugs in clinical testing, including Phase III studies for chronic dermal wounds.
 -- Quadra Logic Technologies Inc. (NASDAQ: QLTIF), Vancouver, B.C. is the world leader in the development of new pharmaceutical products and applications for Photodynamic Therapy (PDT), an emerging medical field that uses light-activated drugs in the treatment and prevention of cancer and other diseases.
 -- Targeted Genetics Corporation of Seattle is a leader in the development of integrated gene therapy treatments for acquired and inherited diseases. Formerly a subsidiary of Immunex Corporation, Targeted Genetics has an exclusive, worldwide, field of use license to all Immunex patents and technology useful for gene therapy.
 -- Xillix Technologies Corp., of Vancouver, B.C. is a medical devices company engaged in the research, development and commercialization of medical imaging products which aid in the earlier detection of cancer. Xillix is listed on the Toronto Stock Exchange under the trading symbol "XLX."
 Conference management is being provided by Russell-Welsh, Inc., a biomedical communications firm.
 -0- 6/7/93
 /CONTACT: Katharine A. Russell of Russell-Welsh, Inc., 415-312-0700, for Medical Investments Northwest/

CO: Medical Investments Northwest ST: Oregon, Washington IN: MTC SU:

JT-LR -- NY008 -- 5849 06/07/93 09:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 7, 1993

Related Articles
MKG Financial Group Invites You to Listen to a Replay of Its Presentations At the 4th Annual Northwest Investors Conference.
Advanced Power Technology, Inc. to Present at Sixth Annual Northwest Investors Conference September 15, 2001.
Bank of the Northwest to Present at Sixth Annual Northwest Investors Conference September 15, 2001.
FLIR Systems, Inc. to Present at Sixth Annual Northwest Investors Conference September 15, 2001.
Bioject Medical Technologies, Inc. to Present at Sixth Annual Northwest Investors Conference September 15, 2001.
Life Sciences CEO & Investor Forum Slated for March 22 - 23, 2004; Invest Northwest(TM) to Feature Presentations from the Most Innovative Pacific...
Leading Biotech Executives and Investors Scheduled to Speak At BIO VentureForum West 2003; Discounted Early Registration Ends Today.
Leading Biotechnology Investors to Participate in Invest Northwest 2004; Demonstrates Increasing Prominence of Northwest Biotechnology.
Leading Biotechnology and Medical Device Companies to Participate in Invest Northwest(C) 2004; Application deadline is December 5, 2003.
Invest Northwest Life Sciences CEO & Investor Forum Slated for March 21 - 22, 2006.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters